Myriad Genetics
MYGN
260 hedge funds and large institutions have $2.22B invested in Myriad Genetics in 2018 Q1 according to their latest regulatory filings, with 36 funds opening new positions, 93 increasing their positions, 82 reducing their positions, and 23 closing their positions.
57% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 23
54% more call options, than puts
Call options by funds: $11.2M | Put options by funds: $7.24M
13% more repeat investments, than reductions
Existing positions increased: 93 | Existing positions reduced: 82
4% more funds holding
Funds holding: 250 → 260 (+10)
0.08% less ownership
Funds ownership: 107.84% → 107.76% (-0.08%)
13% less capital invested
Capital invested by funds: $2.56B → $2.22B (-$341M)
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$25M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$18.6M |
| 3 |
SI
Sensato Investors
San Francisco,
California
|
+$17.5M |
| 4 |
BlackRock
New York
|
+$11M |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
+$5.94M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wells Fargo
San Francisco,
California
|
-$23.4M |
| 2 |
D.E. Shaw & Co
New York
|
-$19.4M |
| 3 |
BIM
Bogle Investment Management
Newton Lower Falls,
Massachusetts
|
-$10.1M |
| 4 |
Two Sigma Advisers
New York
|
-$9.16M |
| 5 |
Millennium Management
New York
|
-$6.65M |
MYGN Hedge Fund Activity: Q1 2018 in Review
260 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Myriad Genetics (MYGN) for Q1 2018, worth a combined $2.22B — down 13% from $2.56B a quarter earlier.
Buyers outnumbered sellers: 36 funds opened new MYGN positions and 23 closed out — a net gain of 13 holders — while 93 added to existing stakes and 82 trimmed.
The largest buyer was Goldman Sachs, adding an estimated $25M. The largest seller was Wells Fargo, cutting an estimated $23.4M.
- 260 institutional investors held Myriad Genetics (MYGN) as of Q1 2018, up from 250 in Q4 2017.
- Funds reported $2.22B of Myriad Genetics stock for Q1 2018, down 13% quarter-over-quarter.
- 36 funds opened new Myriad Genetics positions in Q1 2018 and 23 closed out, a net change of +13 holders.
- The largest Myriad Genetics buyer in Q1 2018 was Goldman Sachs, an estimated $25M added.
- The largest Myriad Genetics seller in Q1 2018 was Wells Fargo, an estimated $23.4M sold.
Based on aggregated 13F filings for Q1 2018.